FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

Based on material, the prefilled syringe market is bifurcated into glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held a larger market share in 2022.

Prefilled syringes (PFSs ... Practices related to predrawing the vaccine into unmarked plastic syringes were observed that could impact patient safety and reduce vaccine potency.

The Food and Drug Administration (FDA) has approved a prefilled syringe formulation of Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional. The approval is based on studies ...

(RTTNews) - Halozyme Therapeutics Inc. (HALO) announced that argenx has received U.S. Food and Drug Administration approval of VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod ...

April 10 (Reuters) - The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's (ARGX.BR), opens new tab blockbuster immune disorder drug ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...